(Q24240202)

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Recombinant human erythropoietin in the treatment of the anaemia of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Impact of epoetin beta on quality of life in patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

21 January 2018

Age, anemia, and fatigue

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin improves quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The relationship between psychologic distress and cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Anemia in cervical cancer patients: implications for iron supplementation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin treatment in metastatic breast cancer--effects on Hb, quality of life and need for transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A new look at the statistical model identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Confidence intervals for the number needed to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Calculating the number needed to treat for trials where the outcome is time to an event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Expression of erythropoietin receptor splice variants in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin and erythropoietin receptor expression in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin for patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin, uncertainty principle and cancer related anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Efficacy and safety of epoetin alfa in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Exercise for the management of cancer-related fatigue in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Expression cloning of the murine erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Introduction: Rationale, Potentials, and Promise of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Risks of blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Risks of blood transfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Chemotherapy-induced anemia in adults: incidence and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The impact of hemoglobin levels on fatigue and quality of life in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The erythropoietin receptor in normal and cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The level of haemoglobin in anaemic cancer patients correlates positively with quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin receptor function and expression in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

The anaemia of cancer: death by a thousand cuts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Treatment resistance of solid tumors: role of hypoxia and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Hypoxia and anemia: effects on tumor biology and treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Mechanism of erythropoietin-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Cisplatin-associated anemia: an erythropoietin deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin regulates tumour growth of human malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes

21 January 2018

1 reference

12 December 2020

[Erythropoietin and cisplatin-induced neuropathies in cancer patients]

1 reference

12 December 2020

Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study

1 reference

12 December 2020

Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies

1 reference

12 December 2020

Erythropoietin: physiology and pharmacology update

1 reference

12 December 2020

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

12 December 2020

Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

1 reference

12 December 2020

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans

1 reference

12 December 2020

Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties

1 reference

12 December 2020

Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas.

1 reference

12 December 2020

Structural characterization of human erythropoietin

1 reference

12 December 2020

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

12 December 2020

The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study

1 reference

12 December 2020

Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis

1 reference

12 December 2020

Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a ra

1 reference

12 December 2020

Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition

1 reference

12 December 2020

Role of red blood cells in pharmacokinetics of chemotherapeutic agents

1 reference

12 December 2020

Erythropoietin for patients undergoing radiotherapy: a pilot study

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

1 reference

12 December 2020

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

12 December 2020

Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study

1 reference

12 December 2020

Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy

1 reference

12 December 2020

Recombinant human erythropoietin treatment for chemotherapy-related anemia in children

1 reference

12 December 2020

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Erythropoietin for anaemia in cancer patients

1 reference

12 December 2020

Symptomatology of anemia

1 reference

12 December 2020

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

12 December 2020

Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study.

1 reference

12 December 2020

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care

1 reference

12 December 2020

Anti-Epo receptor antibodies do not predict Epo receptor expression

1 reference

12 December 2020

Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review

1 reference

12 December 2020

Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo

1 reference

12 December 2020

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

1 reference

12 December 2020

Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies

1 reference

12 December 2020

[Erythropoietin in patients with head and neck carcinomas?]

1 reference

12 December 2020

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and N

1 reference

12 December 2020

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer

1 reference

12 December 2020

Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group

1 reference

12 December 2020

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

1 reference

12 December 2020

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

1 reference

12 December 2020

Preoperative epoetin alfa in colorectal surgery: a randomized, controlled study

1 reference

12 December 2020

Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

1 reference

12 December 2020

Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.

1 reference

12 December 2020

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

1 reference

12 December 2020

Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

1 reference

12 December 2020

Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study

1 reference

12 December 2020

Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer

1 reference

12 December 2020

A single institutional experience: is epoetin alpha effective in anemic children with cancer?

1 reference

12 December 2020

Psychological outcomes associated with anemia-related fatigue in cancer patients

1 reference

12 December 2020

Is epoetin alfa a treatment option for chemotherapy-related anemia in children?

1 reference

12 December 2020

Localization of cells producing erythropoietin in murine liver by in situ hybridization

1 reference

12 December 2020

Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy

1 reference

12 December 2020

Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO)

1 reference

12 December 2020

Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy

1 reference

12 December 2020

Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.

1 reference

12 December 2020

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

12 December 2020

Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly

1 reference

12 December 2020

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

12 December 2020

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

12 December 2020

Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

1 reference

12 December 2020

Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies

1 reference

12 December 2020

Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.

1 reference

12 December 2020

Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

1 reference

12 December 2020

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

12 December 2020

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy.

1 reference

12 December 2020

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

1 reference

12 December 2020

Schwann cells in neuroblastoma express erythropoietin

1 reference

12 December 2020

Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta

1 reference

12 December 2020

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy

1 reference

12 December 2020

Hemostasis and malignancy

1 reference

12 December 2020

The use of fractional polynomials to model continuous risk variables in epidemiology

1 reference

12 December 2020

Reducing the costs of phase III cardiovascular clinical trials

1 reference

12 December 2020

Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.

1 reference

12 December 2020

Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)

1 reference

12 December 2020

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response

1 reference

12 December 2020

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

12 December 2020

A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue

1 reference

12 December 2020

Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.

1 reference

12 December 2020

Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization

1 reference

12 December 2020

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

1 reference

12 December 2020

Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer

1 reference

12 December 2020

Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients

1 reference

12 December 2020

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer

1 reference

12 December 2020

Subcutaneous recombinant-human-erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer

1 reference

12 December 2020

Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.

1 reference

12 December 2020

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)

1 reference

12 December 2020

The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007303.PUB2

7 January 2021